17

Chairman: Virgil Schijns and M.E. Lanio

Keynote address: The important role of immunopotentiators in modern vaccines. V. Schijns, The Netherlands

MedDC: a fully functional human DC-like artificial antigen presenting cells. K. Yokokawa, Japan

Polysaccharide adjuvants and their mechanism of action. N. Petrovsky, Australia

Sticholysin II (St II), a pore forming protein isolated from the sea anemone Stichodactyla helianthus with immunomodulator properties. M.E. Lanio, Cuba

Use of CD40 antibodies as potent adjuvants. A Heath, UK

HCMV tegument particles as vaccine vectors. W Britt, USA

17

Monitoring T cell responses: From animal models to the clinic. P. M. Dubois, Belgium

Current Perspectives on the Preclinical Testing of Preventive Vaccines & Adjuvants. S. Sifontes, Cuba.

Pending title. A. Batista, Cuba.

18

Chairman: C. Czerkinsky, A Harandi, and E. Lavelle

Keynote address: Compartmentalization of mucosal immune response. Cecil Czerkinsky, France

Pending title. A. Harandi, Sweden

Mechanism of action of mucosal vaccine adjuvants. E. Lavelle, Ireland

Dendritic cell-mediated induction of mucosal cytotoxic responses following MUCOSAL immunization with Cholera toxin derivatives. F. Anjuère, France

NASVAC, a nasal vaccine candidate for chronic Hepatitis B immunotherapy. V. Muzio, Cuba

Chairman: L.A. Mulard and O. Cabrera

Synthetic carbohydrate-protein conjugates as potential vaccines against Shigella flexneri serotype 2a. L.A. Mulard, France

Design and characterization of protein-dimeric polysaccharide conjugate against Neisseria meningitidis serogroups A and C. O. Cabrera, Cuba

Current Perspectives on the Preclinical Testing of Preventive Vaccines & Adjuvants. S. Sifontes, Cuba.

Vibrio cholera bacterial ghost as selivery system induces immunological responses against Leishmania major glycoptrotein gp63 DNA IN Balb/c mice. F. Mahboudi, Iran

Immunological evaluation of a new vaccine candidate based on the adjuvant effect of the recombinant HBV surface and core antigens on CR3, an HIV-based multiepitopic protein. E. Iglesias, Cuba

19

Chairman: Martin Friede and RL Solís

Keynote address: Pending title. Martin Friede, Sweden

Influence of Proteoliposome on Alum absorbed MenB vaccines. D. González, Cuba

Proteoliposome and Cochleate adjuvants. O. Pérez, Cuba

Effect of CpG inclusion onto Proteo-Cochleate. J. del Campo, Cuba

Response to Malaria antigen onto Cochleate. G. Bracho, Cuba

New Cochleate from Vibrio cholerae. R. Acevedo, Cuba

19

Chairman: C Leclerc and A Alerm

20

Reuniones Bilaterales

14:00

Salida para la Habana

A-1

Immunomodulatory effect of a M. tuberculosis expression library on the protective response of BCG immunized mice against a mycobacterial challenge. López Y., Yero D., Sifontes S., Infante J. F., Pérez M., Sarmiento M.E., Díaz D., Parajón E., and Acosta A. Cuba

A-2

Sticholysin II (St II), a pore forming protein isolated from the sea anemone Stichodactyla helianthus with immunomodulator properties. Calderón L., Facenda E., Mesa C., Machado L., Fernández L.E., Alvarez C., Labrada A., and Lanio M.E. * Cuba

B-1

Preclinical toxicity testing plan of Cochleate in Sprague Dawley rats. Infante J.F, Sifontes S., Lastre M., del Campo J., Bracho G., Sosa E., Pérez V., Díaz D., Hernández T., Torres V., Rodríguez N., Fariñas M., Zayas C., and Pérez O. Cuba

B-2

Comparison of divergent delivery methods for an HIV DNA vaccine in preclinical model. Maria Malm*, Marja Pirinen, Marianne Karlsberg, Tuula Myllymäki, Andres Männik, Mart Ustav, Vesna Blazevic. Finland

C-1

Outer membrane vesicles of Neisseria lactamica as a potencial mucosal adjuvant. Sardiñas G. *, Reddin K., Pajon R., and Gorringe A. Cuba

D-1

Physico-chemical and immunological characterization of new meningococcal C polysaccharide-tetanus toxoid conjugate. Cuello M.*, Cabrera O., Martinez I., Lemercinier X., Bolgiano B., Crane D., del Campo J.M., Camaraza M.A., Sotolongo F., Pérez O., and Sierra G. Cuba

D-2

Induction of Full Anti-tumour Protection by Post-operative Immunization With GM3/VSSP Vaccine in a Pre-Clinical Mouse Melanoma Model. Gabri M.R., Mazorra Z.*, Ripoll G.V., Mesa C., Fernandez L.E., Gomez D.E., Alonso D.F. Cuba

E-1

Preclinical evaluation in mice of the immunogenicity of a novel adjuvanted anti-allergic vaccine. Ramírez W., Labrada A., Facenda E., Bourg V., González B., Lastre M. and Pérez O. Cuba

E-2

Immunological evaluation of a new vaccine candidate based on the adjuvant effect of the recombinant HBV surface and core antigens on CR3, an HIV-based multiepitopic protein. Iglesias E. *, Thomson R., Carrazana Y., Lobaina Y., García D., Sánchez J., García J., Cruz O., Brown E., Martín A., Muzio V. and Aguilar J.C. Cuba

E-3

Evaluation of the recombinant fusion protein expressed in Escherichia coli that includes domain III of the Dengue Type 1 viral envelope protein in nonhuman primates adjuvated in freund and aluminum hydroxide. Bernardo L. *, Izquierdo A., Alvarez M., Rosario D., Prado I., López C., Sierra B., Martínez R., Castro J., Santana E., Hermida L., Guillen G. and Guzmán M.G. Cuba

E-4

Western blot profile in sera from nonhuman primates immunized with domain III of the Dengue type 1 and 2 envelope proteins adjuvated in freund and aluminum hydroxide. Cabezas S. *, Bernardo L., Izquierdo A., Alvarez M., Rosario D., López C., Martínez R., Castro J., Hermida L., Guillen G. and Guzmán M.G. Cuba

E-5

Influence of the aluminum-based adjuvant and formulation over the immune-response to a multi-epitopic protein from HIV-1 co-administered with surface and core antigens of HBV. Iglesias E., Franch O., Carrazana Y., Lobaina Y., García D., Sánchez J., Sánchez J., Urquiza D., Cruz O., Muzio V.L., Guillén G., Aguilar J.C. Cuba

F-1

The antibody response to recombinant protein NMB1126 from Neisseria meningitidis with different adjuvants. Niebla O*., Yero D., Cobas K., and Pajón R. Cuba

F-2

A new attractive method for refolding and increasing the immunogenicity of recombinant antigens. Niebla O.*, Delgado M., Yero D., de la Caridad Y., and Pajón R. Cuba

F-3

New trends in adjuvants: use of Proteoliposome as adjuvant in potential candidate vaccines. Hernández J. * and Pérez O. Cuba

F-4

Cholera vaccine candidate proteoliposome as a potential adjuvant. Pérez J.L., González Y., Año G., Cedré B., Valmaseda T., Acevedo R., González L., Cabreras R.A., Talavera A., Martínez I., Pérez O. and García L. Cuba

F-5

Immunogenic properties of a Proteoliposome From Vibrio cholerae O1, El Tor Ogawa. González Y., Pérez J.L., Año G., Cedré B., Valmaseda T., Cabreras R.A., Martínez I., Milián E., Fariñas M., Serrano D., Talavera A. and García L. Cuba

G-1

Intraperitoneal administration of freund´s adjuvant IN neonatal mice negatively influences the levels of bacteremia achieved after challenge with meningococci. González S. *,. Pérez Y.C., Blanco A., Cobas K. and Pajón R. Cuba